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Abstract Bone morphogenetic protein-2 (BMP-2) is a member
of the transforming growth factor L superfamily which induces
bone formation and regeneration, and important steps during
early embryonic development. BMP-2 signals via oligomeriza-
tion of type I and type II serine/threonine kinase receptors. We
report here expression of the extracellular domain of the human
type IA receptor for BMP-2 (BMPR-IA) in Escherichia coli.
This soluble form of BMPR-IA (sBMPR-IA) was purified
employing a BMP-2 affinity column. Gel filtration experiments
and analysis of gel filtration fractions by polyacrylamide
electrophoresis and densitometry reveal that BMP-2 forms a
defined 1:2 complex with sBMPR-IA that can be purified and
hopefully used for crystallization studies.
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1. Introduction
Bone morphogenetic protein-2 (BMP-2) is one of the key
representatives of a group of bone morphogenetic proteins
that were originally de¢ned by their bone and cartilage-induc-
tive activity at non-skeletal sites in vivo [1,2]. Cloning of the
cDNA [3] revealed that BMP-2 belongs to the transforming
growth factor L (TGF-L) superfamily. The TGF-L superfam-
ily is a group of multifunctional cytokines that play important
roles in development and in the control of di¡erentiation and
proliferation. The mouse knockout mutant of the bmp2 gene
is embryonic lethal showing severe defects in cardiac develop-
ment and a missing closure of the proamniotic canal [4].
BMP-2 is synthesized as a 453 residue proprotein, which be-
comes glycosylated, proteolytically cleaved and dimerized
through a single disulphide bridge to yield the mature homo-
dimeric protein consisting of the 114 C-terminal proprotein
residues.
BMP-2 transduces signals into the cell by binding two types
of receptor chains [5]. Cross-linking experiments in whole cells
employing BMP-2 or the highly homologous BMP-4 revealed
that BMP-2 can interact with any of three di¡erent type I
receptors, as BMPR-IA (ALK-3), BMPR-IB (ALK-6) and
ActR-IA (ALK-2), and with two type II receptors BMPR-II
and ActR-II [6,7]. The type II receptors, however, reacted to a
larger extent only when a type I receptor was present [8]. This
is a clear distinction to the TGF-L system where the TGFLR-
II can bind TGF-L on its own whereas TGFLR-I can not [9^
13]. The speci¢cities and a⁄nities reported for the interactions
between BMP-2 and type I receptors are still under discussion
[14]. Both receptor types are membrane-bound proteins with a
110 to 130 amino acid residues long extracellular domain, a
single transmembrane helix and an intracellular part which
comprises a serine/threonine kinase domain. The type II re-
ceptor phosphorylates and thus activates the type I receptor.
The type I receptor then phosphorylates signal transducer
proteins called Smads which upon phosphorlyation translo-
cate to the nucleus and activate speci¢c genes.
While in whole cells homo- and heterodimeric receptors
have been found in the absence of ligand [15], the stoichiom-
etry of the complex between BMP-2 and the receptor ectodo-
mains has not yet been determined. In principle it might be
expected that a dimeric ligand like BMP-2 provides two bind-
ing epitopes for two identical receptor chains. However this
1:2 ratio of binding between dimeric ligand and receptor is
not seen for interleukin-5 (IL-5); here one IL-5 dimer mole-
cule binds only one soluble IL-5 receptor K molecule [16]. In
contrast, a 1:2 stoichiometry has been demonstrated for in-
terferon-Q, which is a homodimer, and its soluble high-a⁄nity
receptor [17,18]. Also higher ratios like 1:4 are conceivable as
monomeric ligands like growth hormone or erythropoietin
bind two identical receptor chains [19,20].
In this study we have expressed the extracellular domain of
the human BMPR-IA (sBMPR-IA) in soluble form in Esche-
richia coli and puri¢ed it to homogeneity using a BMP-2
a⁄nity column. This a⁄nity chromatography step proved
critical to prepare reproducibly and quantitatively a homoge-
neous complex with de¢ned stoichiometry between human
BMP-2 and sBMPR-IA. Gel ¢ltration and gel electrophoresis
provided direct evidence for the formation of a 1:2 complex
between BMP-2 and sBMPR-IA. The puri¢cation of the de-
¢ned BMP-2WBMPR-IA2 complex is the prerequisite for crys-
tallization and X-ray analysis.
2. Materials and methods
2.1. Expression and puri¢cation of recombinant BMP-2 and soluble
BMPR-IA
Recombinant human BMP-2 representing the mature part of BMP-
2 (residues 283^396 of the preproprotein) plus an N-terminal MA
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extension was expressed in E. coli and puri¢ed to homogeneity as
previously described [21]. The molar extinction coe⁄cient determined
by means of amino acid composition analysis was A280 = 40510 M31
cm31. Based on the amino acid sequence a molecular weight of
25.8 kDa was calculated for the disulphide linked BMP-2 homodimer.
The extracellular domain of human BMPR-IA (BMPR-IA ECD)
comprising residues 24^152 of the preprotein [22] plus an N-terminal
GSGAMA extension was expressed in E. coli as a soluble thioredoxin
fusion protein. The gene encoding human BMPR-IA ECD was cloned
into a derivative of the expression vector pET-32a (Novagen) at the
NcoI and Bpu1102I restriction enzyme sites. The derivative di¡ers
from the original pET-32a through deletion of basepairs 223^297.
The expression plasmid was transformed in E. coli strain
AD494(DE3), and fusion protein synthesis was induced by addition
of 1 mM isopropyl-L-D-glucopyranoside. After sonication of the cells
the soluble fusion protein was prepared by chelating chromatography
using a nickel column. After cleavage of the fusion protein by throm-
bin (2 Wg thrombin per mg fusion protein) at room temperature for
4 h, the sBMPR-IA was separated from the thioredoxin by anion
exchange chromatography with a fractogel EMD-TMAE column
(Merck). The column was equilibrated in 20 mM Tris/HCl, pH 7.4,
and bound protein was eluted with a linear NaCl gradient from 0 to
1 M NaCl. The BMPR-IA ectodomain was ¢nally puri¢ed through
chromatography on a BMP-2 a⁄nity matrix equilibrated in 10 mM
HEPES, pH 7.4, 500 mM NaCl, 3.4 mM EDTA. The matrix was
prepared by binding of 10 mg BMP-2 to 10 ml BrCN activated Se-
pharose 6B gel (Pharmacia) according to the manufacturers instruc-
tions. Bound sBMPR-IA was eluted with 4 M MgCl2. The expected
N-terminus GSGAMAQNLD was con¢rmed by sequence analysis.
The molar extinction coe⁄cient was A280 = 4980 M31 cm31 as cali-
brated by amino acid composition analysis. Based on the amino
acid sequence a molecular weight of 14.7 kDa was calculated for
sBMPR-IA.
2.2. Gel ¢ltration chromatography and SDS^polyacrylamide gel
electrophoresis
Protein samples were run at a £ow rate of 0.5 ml/min on a Superdex
200 HR 10/30 column (Pharmacia). The column was equilibrated at
room temperature in 20 mM Tris/HCl, pH 7.5, 700 mM NaCl. The
eluant was monitored by a UV detector at a wavelength of 280 nm.
Bovine serum albumin (66.4 kDa), ovalbumin (43 kDa) and ribonu-
clease A (13.7 kDa) were used to calibrate the column. The void
volume V0 of the column was determined using Blue Dextran 2000.
The Kav for the individual proteins was calculated as follows:
Kav = (VR3V0)/(Vc3V0) with VR as retention volume of the protein
and Vc as the geometric bed volume in ml. A plot of Kav versus log
MW for a standard run resulted in a straight line with a correlation
coe⁄cient R2 = 0.99. Linear regression gave the equation log
MW =32.975*Kav+5.898. This equation was used to calculate the
apparent molecular weight. All samples were prepared in 10 mM
Tris/HCl, pH 7.5, 150 mM NaCl. Mixtures of BMP-2 and sBMPR-
IA were allowed to equilibrate at room temperature for 20 min before
being applied to the column. All samples had protein concentrations
1.0^1.2 mg/ml and sample volumes 40^80 Wl.
SDS^PAGE was performed according to the method of Laemmli
[23] using 12% acrylamide gels. Densitometry of Coomassie stained
gels was done using the program Scion Image, version 3b (Scion
Corporation, MD, USA).
3. Results
We established an E. coli expression system for the extra-
cellular domain of BMP receptor type IA (sBMPR-IA, see
Section 2). After thrombin cleavage of the thioredoxin fusion
protein and anion exchange chromatography we obtained
routinely 2.5 mg sBMPR-IA per liter culture medium (4.2 g
wet cells). Although this material is soluble and appears uni-
form on SDS^PAGE, reversed phase HPLC analysis showed
that it is composed of several folding isomers (data not
shown). Homogeneous, binding competent sBMPR-IA could
only be puri¢ed by means of a⁄nity chromatography on a
BMP-2 column. The ¢nal yield is 0.5 mg sBMPR-IA per liter
culture medium. The electrophoretic mobility of sBMPR-IA
corresponds to an apparent molecular weight of 16 kDa under
non-reducing conditions (Fig. 1). Under the same conditions
(non-reducing) BMP-2 runs at about 28 kDa similar to the
theoretical molecular weight of 25.8 kDa for the disulphide
linked dimer. The sBMPR-IA stains 1.3-fold less intense with
Coomassie than BMP-2. This can be seen by direct compar-
ison of the sBMPR-IA band with the BMP-2 band in Fig. 1
where equal amounts were loaded on the gel (1 Wg each).
This non-glycosylated sBMPR-IA provided us with suitable
material for determining the stoichiometry of ligand binding
and preparation of the complex with BMP-2.
The isolated components were chromatographed on the
Superdex 200 HR 10/30 column. The puri¢ed sBMPR-IA
protein was eluted in a uniform peak (Fig. 2a) shortly after
ovalbumin (43 kDa). The apparent molecular weight of 28
kDa calculated from the elution volume is considerably larger
than the theoretical molecular weight of 14.7 kDa calculated
from the amino acid sequence. The possibility that sBMPR-
IA forms a homodimer in solution is unlikely, because pre-
liminary analysis of sBMPR-IA by cross-linking and by elec-
trospray mass spectrometry did not detect an sBMPR-IA
dimer (data not shown). Instead a highly asymmetric molec-
ular shape might be responsible for the unusually large Stokes
radius during gel ¢ltration (see Section 4). Free BMP-2 was
eluted shortly before the marker RNase A (Fig. 2b). Concern-
ing the calculated molecular weight of 25.8 kDa for the disul-
phide linked BMP-2 homodimer its apparent molecular
weight of 17 kDa was unexpected. As BMP-2 could only be
recovered in maximum amount after chromatography at
NaCl concentrations larger than 500 mM we suggest that
the retarded elution during chromatography is due to electro-
static interactions with the gel matrix (see Section 4). We then
titrated a constant amount of 1.2 nmol BMP-2 with increasing
concentration of sBMPR-IA. When a 3-fold excess of
sBMPR-IA over BMP-2 was present, a major peak with ap-
parent molecular weight of 55 kDa was clearly separated from
a minor peak corresponding to excess sBMPR-IA (Fig. 2c).
PAGE analysis of 0.5 ml fractions taken from the gel ¢ltra-
tion clearly shows the complex between BMP-2 and sBMPR-
IA by occurrence of both proteins in fractions 29^32, whereas
Fig. 1. SDS^PAGE under non-reducing conditions of sBMPR-IA,
BMP-2 and fractions of gel ¢ltration chromatography of a 1:3 mix-
ture BMP-2/sBMPRIA. PM, protein marker; IA, sBMPR-IA; B2,
BMP-2. Gel ¢ltration fractions (0.5 ml) of 1:3 mixture BMP-2/
sBMPR-IA are indicated with fraction number (see Fig. 2c). BMP-
2:sBMPR-IA standard: standard mixtures of BMP-2/sBMPR-IA at
1:1 and 1:2 molar ratios.
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the excess sBMPR-IA is seen in fractions 33 and 34 (Fig. 1).
No free BMP-2 was detected, and no higher order complexes
were eluted. When a 1:2 mixture of BMP-2 and sBMPR-IA
was chromatographed, the whole protein eluted as a single
peak (Fig. 2d). Only minor amounts of free protein were dis-
cernible as a slight shoulder. The apparent molecular weight
of 53 kDa of this complex is in good agreement with the
calculated molecular weight of 55 kDa for a 1:2 complex of
BMP-2 and sBMPR-IA. A mixture of equimolar amounts of
BMP-2 and sBMPR-IA yielded three chromatographic peaks
(Fig. 2e): a major peak with apparent molecular weight of
50 kDa, a shoulder with 36 kDa and a third peak with
18 kDa corresponding to unbound BMP-2. The main protein
peak eluting at Ve = 14.4^14.6 ml with an apparent molecular
weight of 50^55 kDa is compatible with the molecular weight
of the 1:2 complex. Whereas the apparent molecular weight of
36 kDa of the shoulder observed only after separation of the
1:1 mixture is similar to the molecular weight of a 1:1 com-
plex (41 kDa). The third peak is identi¢ed as excess BMP-2
because its apparent molecular weight of 18 kDa is very close
to the 17 kDa obtained for BMP-2 alone and PAGE analysis
reveals that it migrates as BMP-2 (data not shown). In sum-
mary, a surplus of free receptor was obtained in the 1:3 mix-
ture and a surplus of free BMP-2 in the 1:1 mixture. Only at
the 1:2 molar ratio both proteins were completely bound into
the complex.
The quantitative protein composition of the chromato-
graphed fractions was determined by PAGE analysis and sub-
sequent densitometry of the Coomassie stained proteins (Ta-
ble 1). On the same gel 1:1 and 1:2 mixtures of BMP-2 and
sBMPR-IA were analyzed. PAGE of the gel ¢ltration frac-
tions of the 1:3 BMP-2/sBMPR-IA mixture reveals the com-
plex formation by coelution of BMP-2 and sBMPR-IA in
fractions 29^32, corresponding to Ve = 14.0^16 ml (Fig. 1).
The ratio of the stain of the BMP-2 band relative to the
sBMPR-IA band clearly shows that the complex eluting
with Ve = 14.4^14.6 ml (MW = 50^55 kDa) is compatible
with the 1:2 complex. E.g. densitometrical analysis of the
protein bands in fraction 30, which is the peak fraction, gives
a ratio of 1.14 for the peak integrals of the BMP-2 band
relative to the sBMPR-IA band. This is very close to the ratio
of 1.13 measured for the 1:2 molar ratio of BMP-2 and
sBMPR-IA. If the complex was formed with a 1:1 stoichiom-
etry, we would expect a ratio of 2.19, which is clearly not the
case (Table 1). This is a third evidence that BMP-2 forms a
1:2 complex with sBMPR-IA, besides the evidences arising
from the gel ¢ltration chromatography. The composition of
the peak with shoulder in Fig. 2e is clearly di¡erent from the
1:2 complex. The ratio lies between the 1:1 and the 1:2 stoi-
Fig. 2. Chromatographs of the gel ¢ltration runs with A280 on the
y-axis and elution volume Ve on the x-axis. a: sBMPR-IA; b: BMP-
2; c: 1:3 mixture of BMP-2 and sBMPR-IA; d: 1:2 mixture of
BMP-2 and sBMPR-IA; e: 1:1 mixture of BMP-2 and sBMPR-IA.
The positions of the protein molecular weight standards albumin
(66.4 kDa), ovalbumin (43 kDa) and ribonuclease A (13.7 kDa) are
indicated in panel a.
Table 1
1:2 stoichiometry of BMP-2/sBMPR-IA complex derived from densitometry of chromatographic fractions after SDS^PAGE
Run BMP-2:sBMPR-IA ratio of peak integrals
Fraction 1:2 BMP-2:sBMPR-IA 1:1 BMP-2:sBMPR-IA
29 30 31
c: 1:3 mixture BMP-2:sBMPR-IA 1.23 þ 0.05 1.06 þ 0.02 1.46 þ 0.20 1.05 þ 0.07 1.85 þ 0.05
d: 1:2 mixture BMP-2:sBMPR-IA 1.10 þ 0.02 1.14 þ 0.07 1.50 þ 0.07 1.13 þ 0.05 2.19 þ 0.08
e: 1:1 mixture BMP-2:sBMPR-IA 1.46 þ 0.50 1.44 þ 0.09 1.71 þ 0.10 1.06 þ 0.08 2.44 þ 0.39
0.5 ml fractions of gel ¢ltration experiments c^e presented in Fig. 2 were subjected to SDS^PAGE. The protein amount of the bands in each
lane was determined by densitometry of the Coomassie blue stained gels. The ratio between the peak integrals of BMP-2 and sBMPR-IA bands
was calculated. Each gel was calibrated using internal standards of 1:2 and 1:1 molar ratios of BMP-2:sBMPR-IA (see Fig. 1). All reported
values are the mean of two measurements þ mean deviation.
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chiometry (Table 1). The quantitative analysis is di⁄cult be-
cause the two peaks in Fig. 2e with Ve = 14.6^15.3 ml display
no baseline separation. Probably the major peak is the 1:2
complex and the shoulder represents the 1:1 complex.
4. Discussion
We have established an E. coli expression system for the
extracellular domain of human BMP receptor type IA
(sBMPR-IA). Due to the a⁄nity chromatography step in
the preparation the sBMPR-IA is fully binding competent.
The KD for the binding of BMP-2 to sBMPR-IA is about
1 nM as determined by biosensor measurements using immo-
bilized sBMPR-IA [24]. A homogeneous and functional pro-
tein is critical for performing binding studies and for the
preparation of a homogeneous complex with BMP-2. We
also tested sBMPR-IA expressed with the baculovirus system
in Sf9 cells. The sBMPR-IA from Sf9 cells is heavily glyco-
sylated and migrates as a di¡use band with apparent molec-
ular weight between 24 and 31 kDa, which does not permit
separation from BMP-2 on PAGE (data not shown). In con-
trast the di¡erent electrophoretic mobilities of E. coli sBMPR-
IA and BMP-2 clearly separate the two components during
PAGE which makes densitometrical analysis possible (Fig. 1).
Gel ¢ltration on a Superdex 200 HR 10/30 column allowed
the separation of BMP-2-bound sBMPR-IA from free
sBMPR-IA (Fig. 2c).
Up to now structural data are only available for several
TGF-L like ligands [25^30] and the free activin type II recep-
tor ectodomain [31]. It would be very informative to have a
structure of the BMP-2 ligand bound to its type I receptor.
This goal has been hampered by the lack of a powerful bac-
terial expression system for the receptor ectodomain. Up to
now only a silkworm expression system for a glycosylated
mouse sBMPR-IA has been described [32]. Our E. coli expres-
sion system for the BMPR-IA ectodomain supplies us with
milligram quantities of non-glycosylated sBMPR-IA. With the
isolation of the BMP-2WsBMPR-IA2 complex we have now
established the basis for crystallization trials in order to de-
termine the three-dimensional structure.
The present results provide 3-fold evidence that BMP-2
binds to sBMPR-IA in a de¢ned 1:2 ratio forming a tight
trimeric complex BMP-2WsBMPR-IA2. First, titration of
BMP-2 with sBMPR-IA shows that only at a 1:2 ratio of
BMP-2 to sBMPR-IA there is neither excess sBMPR-IA nor
excess BMP-2 detected by gel ¢ltration analysis (Fig. 2c^e).
Second, the calibration of the Superdex 200 HR 10/30 column
with BSA, ovalbumin and RNase A as molecular weight
standards leads to an apparent molecular weight of 50^55
kDa for the complex eluting after 14.4^14.6 ml. This is in
good agreement with the theoretical value of 55 kDa for the
BMP-2WsBMPR-IA2 complex. Third, quantitative analysis of
the relative amounts of BMP-2 and sBMPR-IA in this iso-
lated complex by PAGE and densitometry con¢rms a 1:2
ratio of BMP-2:sBMPR-IA (Table 1). As BMP-2 is a member
of the cystine knot growth factor superfamily [33,34], it is
interesting to compare the receptor binding stoichiometries
of other members of this protein family. For VEGF the struc-
ture of its complex with domain 2 of the Flt-1 receptor has
been solved [35]. The dimeric VEGF is bound by two receptor
molecules. The same holds true for the complex of NGF with
domain 5 of the TrkA receptor [36]. We propose that this
stoichiometry of two identical receptor chains bound by the
homodimeric ligand is also shared by other members of the
TGF-L superfamily.
The BMP-2 system shows similarities to the IFN-Q system.
As the BMP-2 system the IFN-Q system displays two di¡erent
receptor types. The structure of a complex between IFN-Q and
its soluble high-a⁄nity receptor has been solved [18]. In this
complex two receptor molecules bind the IFN-Q homodimer.
The binding sites place the receptor molecules apart from the
2-fold symmetry axis of the complex. We propose that this
holds also true for the 1:2 complex of BMP-2 with sBMPR-
IA. The X-ray structure of BMP-2 revealed two cavities at the
symmetry axis of the molecule and two identical symmetry-
related ¢nger-helix cavities remote from the symmetry axis
[30]. It is intriguing to speculate that the binding epitope for
sBMPR-IA is near this ¢nger-helix cavity and thus distant
from the symmetry axis. In contrast, we would expect a loca-
tion of the binding epitope near the symmetry axis of the
dimer if a dimeric ligand binds only one receptor chain.
This seems to be the case for the IL-5 system which shows
binding of a single receptor chain by the homodimeric IL-5
[16].
The BMP-2WsBMPR-IA2 complex appears to have a glob-
ular like shape. This is indicated by the good agreement be-
tween the apparent molecular weight of 50^55 kDa during gel
¢ltration and the theoretical molecular weight of 55 kDa. Be-
sides the size complementarity a charge compensation be-
tween BMP-2 and sBMPR-IA is observed. The sBMPR-IA
has a calculated pI of 4.8 compared to BMP-2 with a pI of
8.2. So the negatively charged receptor ectodomain neutralizes
or shields the positive charges of the basic BMP-2 thus pre-
venting unspeci¢c ionic interactions with the column material.
Remarkably the chromatographic mobility of the free proteins
di¡ers from the nearly ideal behavior of the complex. The
sBMPR-IA elutes too early, most likely due to an asymmetric
molecule shape. The extracellular domain of the related acti-
vin type II receptor is about twice as long as thick leading to
an increased Stokes radius compared to a globular protein of
the same molecular weight [31]. The N-protein of phage V
shows a similar behavior during gel ¢ltration which is due
to shape asymmetry [37]. We thus predict that the structure
of sBMPR-IA displays a similar shape asymmetry. The chro-
matographic mobility of the highly basic BMP-2 is retarded
compared to the calibration proteins. As we have observed
that BMP-2 is completely bound to the Superdex 200 column
at a physiological salt concentration of 150 mM (data not
shown) but elutes at NaCl concentrations of 700 mM, we
conclude that BMP-2 makes ionic interactions with sulfate
groups of agarose in the column matrix, probably through
its heparin binding site [21].
It will be interesting to investigate the architecture of the
BMP-2WsBMPR-IA2 complex to determine which kind of in-
teractions are responsible for the molecular recognition be-
tween BMP-2 and sBMPR-IA. With the isolation of the stable
and homogeneous complex assembled from E. coli expressed
recombinant proteins we have settled the basis for crystalliza-
tion trials to open the door for X-ray analysis of the structure.
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